DOCSLIB.ORG

US5296483.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
US5296483.Pdf ||||||||||||||| USOO5296483A United States Patent (19) 11 Patent Number: 5,296,483 Bodor 45 Date of Patent: Mar. 22, 1994 54 BRAIN-SPECIFICANALOGUES OF site-specific/sustained delivery of centrally acting drug CENTRALLY ACTING AMNES species to the brain, are compounds of the formula 75 Inventor: Nicholas S. Bodor, Gainesville, Fla. 73 Assignee: University of Florida, Gainesville, (I) Fla. 21 Appl. No.: 766,502 22 Filed: Sep. 27, 1991 and the non-toxic pharmaceutically acceptable salts Related U.S. Application Data thereof, wherein D is the residue of a centrally acting 60 Division of Ser. No. 505,910, Apr. 4, 1990, Pat. No. primary, secondary or tertiary amine and 5,082,853, which is a division of Ser. No. 208,872, Jun. 20, 1988, Pat. No. 4,933,438, which is a division of Ser. No. 785,903, Aug. 29, 1985, Pat. No. 4,771,059, filed as PCT/US85/00236, Feb. 15, 1985, which is a continu ation-in-part of Ser. No. 584,800, Feb. 29, 1984, aban doned. 51 Int. Cl...................... A61K 31/55; CO7D 401/06 is an unsubstituted or substituted dihydropyridyl, dihy 52 U.S. C. .................................... 514/217; 514/214; droquinolyl or dihydroisoquinolyl radical. The corre 540/586; 546/141; 546/142; 546/145; 546/146; sponding ionic pyridinium, quinolinium and 546/147; 54.6/150; 546/152; 54.6/153; 546/296; isoquinolinium salts 546/297; 546/299 58) Field of Search ....................... 514/213, 214, 217; 540/586 56) References Cited p-N+ X, PUBLICATIONS Thiel, et al., "Chemical Abstracts', vol. 59, 1963, Col. wherein X is the anion of a non-toxic pharmaceuti 6389e-639 a. cally acceptable acid, are also disclosed. Primary Examiner-C. Warren Ivy Assistant Examiner-James H. Turnipseed Attorney, Agent, or Firm-Burns, Doane, Swecker & Mathis 57 ABSTRACT The subject compounds, which are adapted for the 16 Claims, No Drawings 5,296,483 1 2 cerning the nature of the barrier have been proposed. BRAIN-SPECIFICANALOGUES OF CENTRALLY The widely accepted concept describes the boundary as ACTING AMNES a fat-like layer interspersed with small pores, although the BBB is not a simple, anatomically well-defined uni This application is a divisional of application Ser. No. tary physical entity. Shuttleworth, Prog. Exp. Tumor 07/505,910, filed Apr. 4, 1990, now U.S. Pat. No. Res., 17, 279 (1972). Penetration of such a barrier may 5,082,853, which is divisional of application Ser. No. occur by several processes: lipid soluble substances may 07/208,872, filed Jun. 20, 1988, now U.S. Pat. No. passively penetrate into the cells, while small molecules 4,933,438, which is a divisional of application Ser. No. such as water and urea may pass through the pores. In 06/785,903, filed Aug. 29, 1985, now U.S. Pat. No. 10 addition to these simple physical processes, carrier 4,771,059, which is the U.S. national phase of mediated and active transport processes govern the PCT/US85/00236, filed Feb. 15, 1985 and a continua movement of many molecules through the BBB. Thus, tion-in-part of application Ser. No. 06/584,800, filed it is generally accepted that lipid solubility, degree of Feb. 29, 1984, now abandoned. ionic dissociation or protonation and the ability of tem 15 porary combination with membrane constituents affect FIELD OF THE INVENTION delivery through the BBB. It has been shown, for exam The present invention relates to new derivatives of ple, that in the class of barbiturates, a quantitative corre centrally acting amines in which a primary, secondary lation could be established between their ease to pass or tertiary amine function has been replaced with a into the brain (as reflected by the different times of dihydropyridine/pyridinium salt redox system. The 20 onset of anesthetic action) and their lipid/water parti new dihydropyridine analogues are a delivery system tion coefficient. Mark et al, J. Pharmacol and Exp. for the corresponding new quaternary compounds, Therap, 123, 79 (1957). The role of lipid solubility in which are pharmacologically active in vivo and are drug penetration through the BBB is also exemplified characterized by site-specific and sustained delivery to by the better absorption of the sparingly water-soluble the brain. 25 thiamine propyl disulfide (TPD) as compared to the water-soluble thiamine hydrochloride (THCl). BACKGROUND OF THE INVENTION Thomson et al, Ann. Int, Med., 74, 529 (1971). Some The delivery of drug species to the brain is of times materials such as glucose and amino acids are trans seriously limited by transport and metabolism factors ported by active mechanism, characterized by satura and, more specifically, by the functional barrier of the 30 tion, bidirectional molecular specificity, bidirectional endothelial brain capiliary wall, i.e. the blood-brain competitive inhibition and bidirectional countertran barrier or BBB. Site-specific delivery and sustained sport. Fishman, Am. J. Physiol, 206, 836 (1964). delivery of drugs to the brain are even more difficult. Changes in permeability of the BBB can be caused by Indeed, the barriers separating plasma from the brain several pathological and toxicological processes. Par and cerebrospinal fluid (CSF) are complex systems 35 dridge, Connor and Crawford, CRC Crit. Rey. Toxicol., Involving passive and active transport and subserve a 179 (1975). A general increase in the barrier permeabil number of important functions. The boundary between ity, such as a nonspecific breakdown of the barrier has, plasma and the central nervous system (CNS) is much however, several consequences, including cerebral less permeable than that between plasma and other edema. tissue cells to a variety of water soluble substances, such It too is well documented that the BBB is relatively as organic electrolytes, organic acids and bases, as well impermeable to the ionized forms of drugs and other as to large molecules such as proteins. Such a barrier molecules. Drugs which are weak organic electrolytes also provides a path for clearance from the brain of the appear to pass from blood to CSF to reach a steady state breakdown products of cellular metabolism. The CNS ratio characteristic of each molecule according to its and its fluids can be considered basically a three-com 45 pka and the existence of a normal pH gradient between partment system: the blood or the plasma, CSF and blood and CSF. It is clear that it is the most difficult for brain tissue. There is a diffusion-controlled exchange quaternary pyridinium or ammonium salts to penetrate between CSF and the extra-cellular fuid (CF) of the the BBB. brain. It has also been suggested that the permeabilities And removal of substances from the brain and CSF is of blood-CSF and blood-brain barriers are practically SO obviously a significant factor in regulating drug concen identical with respect to drugs and other foreign sub trations in the CNS. There are several efflux processes: stances. Mayer et al., J. Pharmacol and Exp. Therap, bulk flow via the arachnoid villi, diffusion of lipid solu 125, 185 (1959). ble substances into brain and blood, active transport and The BBB is, moreover, basically the result of the fact metabolism by adjacent meninges. Once a drug or me that the endothelial cells in the brain capillaries are 55 tabolite enters the CSF from blood or brain by simple joined by continuous, tight intercellular junctions, such diffusion, it may rapidly be removed, either by nonse that material has to pass through the cells rather than lective bulk flow or by active transport mechanism between them in order to move from blood to brain. It associated with the choroid plexus or other nondefined is interesting that there are areas within the brain, such structures in the CSF compartment. It is generally ac as the subfornical body and the postremia, in which the cepted that highly lipid-soluble drugs leave the CSF capillary cells are not closely linked so that they lack more rapidly than poorly lipid-soluble ones, but the the characteristics of the BBB. They provide the entry barrier to passage of compounds from CSF has only of small amounts of compounds which would not ordi superficial similarity to the blood-CSF barrier. narily enter the barriers. Hoffman and Olszewzki, Neu Drug elimination processes from the brain are signifi rology (Minneap.), 11, 1081 (1961). 65 cantly directly related to drug accumulation in the Foreign compounds which enter organs other than brain. It is generally assumed that efflux in the opposite the central nervous system with ease, may penetrate the direction involves almost the same processes as for CNS slowly or hardly at all. A number of theories con entry, except that the role of the bulk flow and the 5,296,483 3 4. metabolic processes in the brain are not to be over dihydropyridine latentiated prodrug form thereof. looked. Thus, a hydrophilic compound (2-PAM) was made The two elimination processes studied in the earlier lipoidal (i.e. lipophilic) by making its dihydropyridine literature and which can be said to have a certain bear form (Pro-2-PAM) to enable its penetration through ing on the present invention involve elimination from lipoidal barriers. This simple prodrug approach allowed the brain of ionic species. Thus, it is found that non the compound to get into the brain as well as other metabolized ionic species, such as the acetate ion, have organs, but this manipulation did not and could not a three times slower elimination rate from the CSF than result in any brain specificity. On the contrary, such from the blood. Freundt, Arz, Forsch, 23, 949 (1973). approach was delimited to relatively small molecule An even more dramatic change in the elimination rate O quaternary pyridinium ring-containing drug species and was found in the case of a quaternary piperidinium salt.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    THE ORGANIC CHEMISTRY OF DRUG SYNTHESIS VOLUME 3 DANIEL LEDNICER Analytical Bio-Chemistry Laboratories, Inc. Columbia, Missouri LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS New York • Chlchester • Brisbane * Toronto • Singapore Copyright © 1984 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging In Publication Data: (Revised for volume 3) Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." Includes bibliographical references and index. 1. Chemistry, Pharmaceutical. 2. Drugs. 3. Chemistry, Organic—Synthesis. I. Mitscher, Lester A., joint author. II. Title. [DNLM 1. Chemistry, Organic. 2. Chemistry, Pharmaceutical. 3. Drugs—Chemical synthesis. QV 744 L473o 1977] RS403.L38 615M9 76-28387 ISBN 0-471-09250-9 (v. 3) Printed in the United States of America 10 907654321 With great pleasure we dedicate this book, too, to our wives, Beryle and Betty. The great tragedy of Science is the slaying of a beautiful hypothesis by an ugly fact. Thomas H. Huxley, "Biogenesis and Abiogenisis" Preface Ihe first volume in this series represented the launching of a trial balloon on the part of the authors. In the first place, wo were not entirely convinced that contemporary medicinal (hemistry could in fact be organized coherently on the basis of organic chemistry.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • I (Acts Whose Publication Is Obligatory) COMMISSION
    13.4.2002 EN Official Journal of the European Communities L 97/1 I (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 578/2002 of 20 March 2002 amending Annex I to Council Regulation (EEC) No 2658/87 on the tariff and statistical nomenclature and on the Common Customs Tariff THE COMMISSION OF THE EUROPEAN COMMUNITIES, Nomenclature in order to take into account the new scope of that heading. Having regard to the Treaty establishing the European Commu- nity, (4) Since more than 100 substances of Annex 3 to the Com- bined Nomenclature, currently classified elsewhere than within heading 2937, are transferred to heading 2937, it is appropriate to replace the said Annex with a new Annex. Having regard to Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Com- mon Customs Tariff (1), as last amended by Regulation (EC) No 2433/2001 (2), and in particular Article 9 thereof, (5) Annex I to Council regulation (EEC) No 2658/87 should therefore be amended accordingly. Whereas: (6) This measure does not involve any adjustment of duty rates. Furthermore, it does not involve either the deletion of sub- stances or addition of new substances to Annex 3 to the (1) Regulation (EEC) No 2658/87 established a goods nomen- Combined Nomenclature. clature, hereinafter called the ‘Combined Nomenclature’, to meet, at one and the same time, the requirements of the Common Customs Tariff, the external trade statistics of the Community and other Community policies concerning the (7) The measures provided for in this Regulation are in accor- importation or exportation of goods.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,082,853 Bodor 45) Date of Patent: "Jan
    HE US005082853A United States Patent (19) 11 Patent Number: 5,082,853 Bodor 45) Date of Patent: "Jan. 21, 1992 54 BRAIN-SPECIFICANALOGUES OF CENTRALLY ACTING AMNES OTHER PUBLICATIONS Dean et al., CA 86:16522h. 76 Inventor: Nicholas S. Bodor, 7211 SW. 97th Chemical Abstracts, vol. 84, Jun. 7, 1976, p. 447, abstract La., Gainesville, Fla. 32608 No. 164580Z. (*) Notice: The portion of the term of this patent Chemical Abstracts, vol. 81, Aug. 5, 1974, p. 24, abstract subsequent to Sep. 13, 2005 has been No. 20899a. disclaimed. Primary Examiner-Jane T. Fan (21) Appl. No.: 505,910 57 ABSTRACT The subject compounds, which are adapted for the (22 Filed: Apr. 4, 1990 site-specific/sustained delivery of centrally acting drug Related U.S. Application Data species to the brain, are compounds of the formula 60) Division of Ser. No. 208,872, Jun. 20, 1988, Pat. No. 4,933,438, which is a division of Ser. No. 785,903, filed (I) as PCT/US85/00236, Feb. 15, 1985, Pat. No. 4,771,059, which is a continuation-in-part of Ser. No. 584,800, D-O Feb. 29, 1984, abandoned. 51 Int. Cl...................... A61K 31/44; CO7D 211/90 and the non-toxic pharmaceutically acceptable salts 52) U.S.C. .................................... 514/355; 514/345; thereof, wherein D is the residue of a centrally acting 514/307; 514/309; 514/311; 514/312; 514/348; primary, secondary or tertiary amine and 514/350, 514/354; 514/356; 514/357; 514/358; 54.6/316; 54.6/322; 546/326; 546/296; 546/297; 546/301; 546/302; 546/332; 54.6/329; 54.6/342; 546/298; 546/299; 546/300; 54.6/155; 54.6/156; -NO 54.6/157; 546/158; 546/141; 546/142; 546/145; 546/146; 546/147; 54.6/150, 54.6/152; 546/153 58 Field of Search ..............
    [Show full text]
  • United States Patent (10) Patent N0.: US 6,951,860 B2 Mehanna Et A1
    US006951860B2 (12) United States Patent (10) Patent N0.: US 6,951,860 B2 Mehanna et a1. (45) Date of Patent: Oct. 4, 2005 (54) CALCIUM CHANNEL BLOCKERS 5,132,106 A 7/1992 Tuloup et a1. ......... .. 514/223.5 5,134,139 A 7/1992 Kawai et a1. 514/211.07 Inventors: (Us); JinyungSI Mehanna, T_ Kim, Sudbury, Boston, MA 5,144,029 A 9/1992 AdamsWard et 618.1. a1. ............... .. 540/610 (Us) 5,198,433 A 3/1993 Palfreyman et a1. 514/217.11 5,276,026 A 1/1994 Barrrsh et a1. ....... .. 514/212.02 (73> Assignees Messeeheseees Cellege ef Phesmeey, 2:531:33 2 511333 81315152111111: 1:: iii/552:5 Bostons MA (Us) 5,360,809 A 11/1994 Axelsson 618.1. 514/338 _ _ _ _ _ 5,387,592 A 2/1995 Bradbury et a1. ......... .. 514/312 (*) Notlcel sublectto any dlsclalmer?heterm Ofthls 5,496,815 A 3/1996 OZeki et a1. .... .. 514/2242 patent is eXtended or adjusted under 35 5,514,693 A 5/1996 COZZl et a1. .... .. 514/341 U.S.C. 154(1)) by 183 days. 5,607,939 A 3/1997 Kato et a1. ................ .. 514/278 5,623,051 A 4/1997 Catterall et a1. .......... .. 530/324 (21) Appl. NO.Z 09/998,623 OTHER PUBLICATIONS (22) Flled: Oct‘ 31’ 2001 Gialdi et al., Abstract to CA 56:4664g.* (65) Prior Publication Data McMurry, John, Editor of Second Edition, Organic Chem istry, 1984, pp. 742—746.* Us 200301156551“ Aug- 22, 2002 Protiva, et al. of CZ 105,590 of CA59:10010f, Nov.
    [Show full text]